NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
Clinical Trials
36 trialsNCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03599713 2025-08-05
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Phase 2 Completed
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT02196961 2025-04-09
ADMEC-O
University Hospital, Essen
Phase 2 Completed
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04160065 2024-09-23
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
TuHURA Biosciences, Inc.
Phase 1 Completed
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT04393753 2024-05-08
MERKLIN2
4SC AG
Phase 2 Completed
NCT05253144 2024-05-08
Rational-MCC
University of Birmingham
Phase NA Completed
NCT03798639 2024-04-12
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT05422781 2023-11-22
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
Immunomic Therapeutics, Inc.
Phase 1 Completed
NCT02267603 2023-07-05
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01440816 2023-05-15
MCC
OncoSec Medical Incorporated
Phase 2 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT00540566 2022-10-20
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
University of California, Irvine
Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03071757 2022-04-28
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Completed
NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT03458117 2022-03-18
20139157 T-VEC
University of Zurich
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02514824 2020-12-29
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01652547 2020-12-21
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Novartis
Phase 1 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02035657 2018-06-13
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed
NCT02351128 2017-10-18
PHRC-Merkel
University Hospital, Grenoble
Phase 2 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT01526486 2015-05-06
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Emory University
Phase NA Completed
NCT00346385 2015-03-26
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
ImmunoGen, Inc.
Phase 1 Completed
NCT00004922 2013-06-19
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00079131 2013-06-04
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068783 2013-02-28
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00765193 2010-04-15
TBSE
Medical University of Graz
Phase NA Completed